Brentuximab Vedotin

Author：  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.11, Iss.1, 2011-03, pp. : 85-95

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Brentuximab vedotin: Progressive multifocal leukoencephalopathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1431, 2012-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

By Ansell Stephen M  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 99-105

Informa Healthcare

Access to resources Recommend Favorite

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 174-181

John Wiley & Sons Inc

Access to resources Recommend Favorite

Seattle Genetics Inc's brentuximab vedotin [Adcetris] could be priced at more than $US100 000

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 636, 2011-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Brentuximab vedotin: First reports of diarrhoea, neutropenia, elevated ALT, hypophosphataemia, and peripheral neuropathy: case report

By  

Reactions Weekly, Vol. 1, Iss. 1402, 2012-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite